Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost-Utility Analysis.
Peng MenShuli QuZhenqiang SongYanjun LiuChaoyun LiSuo-di ZhaiPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2020)
For T2DM patients inadequately controlled on OADs, lixisenatide was shown to be comparable to basal insulin and premixed insulin in terms of HbA1c and better than both of the latter in terms of both body weight loss and hypoglycemia. Lixisenatide was also a cost-effective treatment option from the perspective of Chinese health insurance.
Keyphrases
- health insurance
- type diabetes
- end stage renal disease
- systematic review
- glycemic control
- ejection fraction
- weight loss
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- healthcare
- cardiovascular disease
- bariatric surgery
- patient reported outcomes
- body mass index
- insulin resistance
- combination therapy
- smoking cessation
- replacement therapy